[{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Immunovant","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Preclinical","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanall Biopharma \/ Immunovant","highestDevelopmentStatusID":"4","companyTruncated":"Hanall Biopharma \/ Immunovant"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Hanall Biopharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hanall Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Nona Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanall Biopharma \/ Nona Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Nona Biosciences"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanall Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Tanfanercept","moa":"receptor molecules","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hanall Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Tanfanercept","moa":"receptor molecules","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hanall Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Tanfanercept","moa":"receptor molecules","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hanall Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Tanfanercept","moa":"receptor molecules","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hanall Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"NurrOn Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH-399A","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hanall Biopharma \/ NurrOn Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Hanall Biopharma \/ NurrOn Pharmaceuticals"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"NurrOn Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"ATH-399A","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanall Biopharma \/ Hanall Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Hanall Biopharma \/ Hanall Biopharma"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HL192","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanall Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Hanall Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"NurrOn Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HL192","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanall Biopharma \/ NurrOn Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Hanall Biopharma \/ NurrOn Pharmaceuticals"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Turn Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Hanall Biopharma","amount2":0.29999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0.29999999999999999,"dosageForm":"Injection","sponsorNew":"Hanall Biopharma \/ Turn Biotechnologies","highestDevelopmentStatusID":"3","companyTruncated":"Hanall Biopharma \/ Turn Biotechnologies"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Vincere Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanall Biopharma \/ Hanall Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Hanall Biopharma \/ Hanall Biopharma"}]

Find Clinical Drug Pipeline Developments & Deals by Hanall Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Leuprolide Acetate is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          April 15, 2025

                          Lead Product(s) : Leuprolide Acetate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : IMVT-1401 (batoclimab) is an anti-FcRn antibody candidate, which is being evaluated for the treatment of active thyroid eye disease.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          March 06, 2025

                          Lead Product(s) : Batoclimab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : HL192(ATH-399A) is a first-in-class small molecule that focuses on activating Nurr1, it is being investigating for treating Parkinson's Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 25, 2024

                          Lead Product(s) : HL192

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : NurrOn Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's cellular reprogramming technology to create innovative therapies.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 28, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Discovery Platform

                          Sponsor : Turn Biotechnologies

                          Deal Size : $300.0 million

                          Deal Type : Licensing Agreement

                          blank

                          05

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Tanfanercept is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          May 06, 2024

                          Lead Product(s) : Tanfanercept

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : HK036 (tanfanercept) is a potentially first-in-class topical anti-inflammatory treatment targeting tumor necrosis factor (TNF). It is being evaluated for the treatment of dry eye disease.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          May 03, 2024

                          Lead Product(s) : Tanfanercept

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : ATH-399A is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 18, 2023

                          Lead Product(s) : ATH-399A

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : NurrOn Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : HL192 (ATH-399A) is a first-in-class small molecule that focuses on activating Nurr1, a master regulator associated with the development and maintenance of dopaminergic neurons, for the potential treatment of Parkinson's Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 12, 2023

                          Lead Product(s) : HL192

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Daewoong Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The collaboration aims to develop small-molecule, first-in-class disease-modifying therapies by targeting the modulation of mitochondrial quality control mechanisms such as mitophagy for Parkinson's patients by leveraging Vincere's proprietary AI platfor...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 12, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery

                          Recipient : Vincere Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative dis...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          May 25, 2023

                          Lead Product(s) : ATH-399A

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Recipient : NurrOn Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank